Facebook
Twitter
LinkedIn
Forward
Disordered Aggression and Violence in the United States
Instructions
Click the red REGISTER button to pay the $10 fee and take the posttest.
Click here to return to the JCP CME article
Overview
Intermittent explosive disorder (IED) is associated with intimate partner assault, the use of weapons to threaten others, and arrests. This behavior can be reduced through pharmacologic and psychosocial interventions. Learn about IED in this CME journal article.
Read the whole article at psychiatrist.com here:
Disordered Aggression and Violence in the United States
© Copyright 2020 Physicians Postgraduate Press, Inc.
Target Audience
Psychiatrists
Learning Objectives
Screen patients for recurrent impulsive aggression and intermittent explosive disorder so that they can be treated if diagnosed
CME Background
Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.
To obtain credit, read the article, correctly answer the questions in the Posttest, and complete the Evaluation. A $10 processing fee will apply.
CME Objective
After studying this article, you should be able to:
- Screen patients for recurrent impulsive aggression and intermittent explosive disorder so that they can be treated if diagnosed
Statement of Need and Purpose
Clinicians lack knowledge about the revision of IED in the DSM-5 stating that it is a disorder of impulsive (vs premediated) aggression; therefore, education is needed to generate awareness of IED risk factors and to facilitate discussion with patients. Additionally, because co-occurring psychiatric disorders are common in IED, clinicians need education on effective screening strategies for early identification and effective treatment of IED.
Release, Expiration, and Review Dates
This educational activity was published in March 2020 and is eligible for AMA PRA Category 1 Credit™ through April 30, 2022. The latest review of this material was February 2020.
Disclosure of off-label usage
The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this article.
Author contributions
Drs Coccaro and Lee had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Funding/support
Partial salary support for the authors came from grants from the National Institutes of Health (RO1 MH104673 and RO1 AA26667, Dr Coccaro) and from the Pritzker Pucker Family Foundation (Dr Coccaro).
Role of the sponsor
The funders had no role in the design and conduct of the study; collection, management, analyses, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Faculty Affiliation
Emil F. Coccaro, MD‡,*
Clinical Neuroscience Research Unit, Department of Psychiatry and Behavioral Neuroscience, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois
Royce J. Lee, MD
Clinical Neuroscience Research Unit, Department of Psychiatry and Behavioral Neuroscience, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois
‡As of May 2020, Dr Coccaro will be affiliated with the Clinical Neuroscience Research Unit, Department of Psychiatry and Behavioral Neuroscience, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois.
*Corresponding author: Emil F. Coccaro, MD, Clinical Neuroscience Research Unit, Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 5841 South Maryland Ave, Chicago, IL 60637 (ecoccaro@yoda.bsd.uchicago.edu)
Financial Disclosure
All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the advisory boards for Otsuka, Alkermes, and Sunovion; has been a member of the Independent Data Safety and Monitoring Committee for Janssen; has been a member of the Steering Committee for Educational Activities for Medscape; and, as a Massachusetts General Hospital (MGH) employee, works with the MGH National Pregnancy Registry, which is sponsored by Teva, Alkermes, Otsuka, Actavis, and Sunovion, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.
Dr Coccaro is on the scientific advisory board of Azevan Pharmaceuticals and is a consultant to Avanir Pharmaceuticals. Dr Lee has received research grants from Azevan Pharmaceuticals and Avanir Pharmaceuticals.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation